PATHFINDER 2 study results indicate more than half of cancers detected by Galleri test were found in early stages, with three-quarters having no current screening options.
Teams complete whole human genome sequencing and analysis in under four hours, demonstrating potential for same-day NICU workflows.
The collaboration combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics expertise to accelerate development of next-generation enzymes.
New TheraPEAK products include mammalian-derived cytokines for immune cell expansion and chemically defined medium for AAV production.
Findings show that early symptom patterns and biomarker data may help forecast which mild traumatic brain injury patients will experience 30-day symptom persistence.
